230 related articles for article (PubMed ID: 17353401)
1. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial.
PKC-DMES Study Group
Arch Ophthalmol; 2007 Mar; 125(3):318-24. PubMed ID: 17353401
[TBL] [Abstract][Full Text] [Related]
2. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
; Aiello LP; Davis MD; Girach A; Kles KA; Milton RC; Sheetz MJ; Vignati L; Zhi XE
Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
[TBL] [Abstract][Full Text] [Related]
3. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
Aiello LP; Vignati L; Sheetz MJ; Zhi X; Girach A; Davis MD; Wolka AM; Shahri N; Milton RC;
Retina; 2011 Nov; 31(10):2084-94. PubMed ID: 21862954
[TBL] [Abstract][Full Text] [Related]
4. The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.
Sheetz MJ; Aiello LP; Davis MD; Danis R; Bek T; Cunha-Vaz J; Shahri N; Berg PH;
Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):1750-7. PubMed ID: 23404115
[TBL] [Abstract][Full Text] [Related]
5. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
Davis MD; Sheetz MJ; Aiello LP; Milton RC; Danis RP; Zhi X; Girach A; Jimenez MC; Vignati L;
Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):1-4. PubMed ID: 18708615
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.
Aiello LP; Clermont A; Arora V; Davis MD; Sheetz MJ; Bursell SE
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):86-92. PubMed ID: 16384948
[TBL] [Abstract][Full Text] [Related]
7. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.
PKC-DRS Study Group
Diabetes; 2005 Jul; 54(7):2188-97. PubMed ID: 15983221
[TBL] [Abstract][Full Text] [Related]
8. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).
Sheetz MJ; Aiello LP; Shahri N; Davis MD; Kles KA; Danis RP;
Retina; 2011 Jun; 31(6):1053-9. PubMed ID: 21386766
[TBL] [Abstract][Full Text] [Related]
9. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.
Do DV; Schmidt-Erfurth U; Gonzalez VH; Gordon CM; Tolentino M; Berliner AJ; Vitti R; Rückert R; Sandbrink R; Stein D; Yang K; Beckmann K; Heier JS
Ophthalmology; 2011 Sep; 118(9):1819-26. PubMed ID: 21546089
[TBL] [Abstract][Full Text] [Related]
10. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
Sahu AK; Majji AB
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6890; author reply 6890-1. PubMed ID: 21123772
[No Abstract] [Full Text] [Related]
11. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
Vinik AI; Bril V; Kempler P; Litchy WJ; Tesfaye S; Price KL; Bastyr EJ;
Clin Ther; 2005 Aug; 27(8):1164-80. PubMed ID: 16199243
[TBL] [Abstract][Full Text] [Related]
12. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.
Do DV; Nguyen QD; Boyer D; Schmidt-Erfurth U; Brown DM; Vitti R; Berliner AJ; Gao B; Zeitz O; Ruckert R; Schmelter T; Sandbrink R; Heier JS;
Ophthalmology; 2012 Aug; 119(8):1658-65. PubMed ID: 22537617
[TBL] [Abstract][Full Text] [Related]
13. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema.
Strøm C; Sander B; Klemp K; Aiello LP; Lund-Andersen H; Larsen M
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3855-8. PubMed ID: 16186374
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema.
Callanan DG; Gupta S; Boyer DS; Ciulla TA; Singer MA; Kuppermann BD; Liu CC; Li XY; Hollander DA; Schiffman RM; Whitcup SM;
Ophthalmology; 2013 Sep; 120(9):1843-51. PubMed ID: 23706947
[TBL] [Abstract][Full Text] [Related]
15. [Evaluate the effectiveness of laser therapy in the treatment of diabetic maculopathy].
Mrugacz M; Krajewska M; Bryl A; Szuszkiewicz M
Pol Merkur Lekarski; 2013 Jun; 34(204):351-4. PubMed ID: 23882935
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment with intravitreal triamcinolone before laser for diabetic macular edema: 6-month results of a randomized, placebo-controlled trial.
Gillies MC; McAllister IL; Zhu M; Wong W; Louis D; Arnold JJ; Wong TY
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2322-8. PubMed ID: 20019369
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial.
Mitchell P; Bressler N; Tolley K; Gallagher M; Petrillo J; Ferreira A; Wood R; Bandello F;
JAMA Ophthalmol; 2013 Oct; 131(10):1339-47. PubMed ID: 23974915
[TBL] [Abstract][Full Text] [Related]
18. Darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in diabetic macular edema: a 3-month placebo-controlled study.
Staurenghi G; Ye L; Magee MH; Danis RP; Wurzelmann J; Adamson P; McLaughlin MM;
Ophthalmology; 2015 May; 122(5):990-6. PubMed ID: 25749297
[TBL] [Abstract][Full Text] [Related]
19. Ruboxistaurin: LY 333531.
Drugs R D; 2007; 8(3):193-9. PubMed ID: 17472415
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial.
Sutter FK; Simpson JM; Gillies MC
Ophthalmology; 2004 Nov; 111(11):2044-9. PubMed ID: 15522370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]